Investigational drug · Phase 2
HRS-2189
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "HRS-2189"
First trial start
2024
Sep 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-2189", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Unresectable or Metastatic Breast Cancer
- Breast Cancer
- Prostate Cancer
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-2189" as an intervention, largest first.
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06679036 · 300 participants (planned) · Start Jan 21, 2025 · Primary completion Oct 30, 2026
Drug: HRS-2189; Fluvustat and 3 more · For: Advanced Unresectable or Metastatic Breast Cancer
Sites: Harbin, China; Zhengzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06568094 · 100 participants (planned) · Start Sep 25, 2024 · Primary completion Dec 2026
Drug: HRS-5041 tablets; Abiraterone Acetate tablets(II) and 6 more · For: Prostate Cancer
Sites: Harbin, China; Shanghai, China
- Study of HRS-2189 Combined HRS-5041 in Prostate CancerNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06738745 · 90 participants (planned) · Start Dec 31, 2024 · Primary completion Jan 31, 2027
Drug: HRS-2189; HRS-5041 · For: Prostate Cancer Metastatic Disease
Sites: Shanghai, China
- A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast CancerRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06974929 · 80 participants (planned) · Start May 22, 2025 · Primary completion Dec 2026
Drug: HRS-6209 Capsules; Letrozole Tablets and 1 more · For: Breast Cancer
Sites: Tianjin, China
- Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant TumorsStatus unknown
Shandong Suncadia Medicine Co., Ltd.Industry
NCT05851092 · 60 participants (planned) · Start May 26, 2023 · Primary completion Dec 31, 2025
Drug: HRS-2189 Tablets · For: Advanced Malignant Tumor
Sites: Harbin, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07639905 · 28 participants · Start Jun 19, 2026 · Primary completion Aug 6, 2026
Drug: HRS-2189 Tablet · For: Malignant Solid Tumor
Sites: Hefei, China
- An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal CancerNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07061210 · 20 participants (planned) · Start Jul 1, 2025 · Primary completion Oct 1, 2026
Drug: HRS-2189; Adebrelimab and 1 more · For: Colorectal Cancer Metastatic
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Unresectable or Metastatic Breast Cancer
- HRS-6209Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Advanced Unresectable or Metastatic Breast Cancer of Adults
- HRS-1358Phase 22 trials
Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
- HRS-9813Phase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors, IPF and PPF
- FluvustatPhase 21 trial
Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.